<DOC>
	<DOCNO>NCT00873730</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety etanercept 100 mg ( 50 mg twice week ) compare 50 mg week adult subject ankylose spondylitis ( AS ) previous failure usual practice therapy Spain .</brief_summary>
	<brief_title>Study Evaluating Etanercept Subjects With Ankylosing Spondylitis Spain</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis ankylose spondylitis , define Modified New York Criteria Ankylosing Spondylitis . 2 . Maintained inflammatory activity 12 week define : ·Axial form : BASDAI high equal 4 ( 010 ) least one follow parameter : . Global assessment disease patient high equal 4 ( On scale 010 ) . Spinal pain high equal 4 visual analogue scale ( VAS ) . Increase erythrocyte sedimentation rate ( ESR ) and/or CRP normality parameter establish laboratory.·Peripheral form : Arthritis enthesitis high equal 1 site least one following : . Global assessment disease patient high equal 4 ( scale 010 ) . Increase erythrocyte sedimentation rate ( ESR ) and/or CRP normality parameter establish laboratory 3 . Failure treatment : Failure least 2 NSAIDs maximum recommend dose least 3 month ( short time case intolerance , toxicity contraindication ) .·In case ankylose spondylitis peripheral joint involvement , salazopyrine use dose 23 g per day and/or methotrexate ( 15 mg/week ) 4 month ( short time case intolerance , toxicity contraindication ) . In case oligoarticular localize involvement enthesis : lack response , discretion investigator , local infiltration and/or synoviorthesis . 4 . Be 1870 year age 5 . Negative result pregnancy test serum screen visit urine baseline visit , do woman , except surgically sterilize least one year menopause . 6 . Sexually active woman childbearing potential must use medically acceptable contraceptive method , include oral , injectable implantable contraceptive method , intrauterine device properly use barrier contraception . A woman childbearing potential define one biologically capable become pregnant . This include woman use contraceptive whose sexual partner either sterile use contraceptive . 7 . Men surgically sterile agree use reliable contraceptive method study . 8 . Ability reconstitute drug selfinject person . 9 . Capability understand voluntarily give write informed consent sign date , specific procedure protocol perform . 10 . Ability store injectable test article 2º 8º C. Exclusion criterion : 1 . Contraindications treatment antiTNF 2 . Complete ankylosis spine 3 . Onset treatment DMARDs 4 week prior baseline ( SSZ , MTX HCQ permit administrate dose maintain stable 4 week prior baseline ) . Furthermore , patient dose prednisone &gt; 10 mg/d equivalent modify 2 week prior baseline visit , whose infiltration perform intraarticular corticosteroid perform 4 week prior screen visit follow treatment one NSAID 2 week prior baseline visit exclude . 4 . Previous treatment TNF inhibitor biological drug 5 . Abnormalities hematology profile define : leukocyte lower equal 3.5 x 10 exponent 9 /L hemoglobin lower equal 8.5 g/L 5.3 mmol/L hematocrit lower equal 27 % platelet low equal 125 x 10 exponent 9 /L serum creatinine high equal 175 mmol/L aspartate aminotransferase alanine aminotransferase high equal 2 time upper limit normality 6 . Important concomitant medical condition , : Class III IV congestive heart failure accord New York Heart Association classificationUncontrolled arterial hypertension ( define screen systolic blood pressure &gt; 160 mm Hg screen diastolic blood pressure &gt; 100 mm Hg ) Myocardial infarction within 12 month screen visit unstable anginaSevere pulmonary disease require hospitalization oxygen therapyDiagnosis multiple sclerosis central nervous system demyelinate disease Presence history confirm blood dyscrasiasCancer history cancer ( resect cutaneous basal cell squamous cell carcinoma ) Serious infection ( infection require hospitalization and/or intravenous antibiotic ) within 1 month administration test article administration active infection screen history recurrent chronic infectionOpen cutaneous ulcersPatients know chronic infection positivity HIV , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) Active tuberculosis infection ( local guideline appropriate screen treatment tuberculosis set antiTNF therapy must follow ) Any condition , investigator 's judgment , might cause study detrimental subject 7 . Pregnant breastfeed woman 8 . Past current psychiatric illness would interfere subject 's ability comply protocol requirement give informed consent . 9 . Treatment live ( attenuate ) vaccine within 4 week prior baseline . 10 . History alcohol drug abuse would interfere subject 's ability comply protocol requirement . 11 . Treatment investigational drug within 3 month screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Effect etanercept subject ankylose spondylitis</keyword>
</DOC>